Federal Rescheduling and Workplace Drug Testing Rules — What Changed

Executive Summary

The Trump administration's April 2026 reclassification of state-dispensed medical marijuana does not override federal workplace safety rules for transportation workers, according to a May 2026 Department of Transportation notice. Despite the historic shift moving certain cannabis products out of Schedule I under the Controlled Substances Act, the DOT has clarified that commercial truck drivers, airline pilots, railroad engineers, and other safety-sensitive transportation employees remain prohibited from using marijuana in any form—medical or otherwise—under existing Department of Transportation drug testing regulations codified at 49 CFR Part 40. This regulatory framework, which predates the rescheduling action and operates independently of DEA scheduling decisions, continues to classify marijuana as a prohibited substance for approximately 12.5 million workers in DOT-regulated industries. The divergence between federal drug scheduling policy and workplace safety enforcement illustrates the complex patchwork of cannabis regulation that persists even as federal policy evolves, creating ongoing compliance challenges for employers, employees, and state medical marijuana programs across all 38 states with legal medical cannabis frameworks.

Why This Matters

This policy affects 12.5 million transportation workers nationwide and exposes the fundamental tension between evolving federal cannabis policy and unchanged workplace safety regulations. The DOT's clarification impacts commercial drivers holding Commercial Driver's Licenses, Federal Aviation Administration-certified pilots and air traffic controllers, Federal Railroad Administration-regulated train operators, Federal Transit Administration transit workers, Pipeline and Hazardous Materials Safety Administration pipeline operators, and United States Coast Guard-regulated maritime workers. These employees face immediate termination and loss of federal certification if they test positive for THC metabolites, regardless of state medical marijuana patient status or off-duty consumption. For the estimated 850,000 medical marijuana patients working in transportation sectors, the DOT notice eliminates any hope that federal rescheduling would provide workplace protections. In states like California, Ohio, Pennsylvania, and Florida with large medical cannabis programs and significant transportation workforces, the policy creates a forced choice between legal medical treatment and employment. The American Trucking Associations reports a current shortage of approximately 78,000 commercial drivers, a gap that workplace cannabis policies may exacerbate as younger workers increasingly view cannabis use as socially acceptable and medically legitimate. The financial implications extend beyond individual workers. Transportation companies face potential liability exposure exceeding $2.8 billion annually in accident-related costs where post-incident drug testing reveals THC presence, even when impairment cannot be established. Insurance carriers have begun incorporating cannabis testing compliance into underwriting decisions, with premium increases of 15-30 percent for fleets with positive test rates above industry averages. Meanwhile, state medical marijuana programs collect approximately $420 million annually in patient registration fees and related revenue, creating fiscal incentives for states to expand patient access—directly conflicting with federal workplace restrictions that limit program participation for large employment sectors.

Background and History

Federal workplace drug testing for transportation workers originated three decades before cannabis rescheduling debates, creating a regulatory structure independent of Controlled Substances Act scheduling.

Origins of Transportation Drug Testing (1988-1991)

The modern framework for federal transportation drug testing emerged from the Anti-Drug Abuse Act of 1988, passed in the final months of the Reagan administration. The legislation required the Department of Transportation to implement drug and alcohol testing for safety-sensitive transportation employees following a series of high-profile accidents involving substance impairment. The January 1987 Conrail-Amtrak collision near Baltimore, which killed 16 people and injured 175, proved particularly influential after toxicology reports revealed the Conrail engineer had used marijuana before the crash. The DOT published its initial drug testing regulations in November 1988, establishing a five-panel drug test covering marijuana, cocaine, opiates, amphetamines, and phencyclidine. The Federal Highway Administration implemented regulations for commercial motor vehicle operators at 49 CFR Part 382 in December 1989, followed by Federal Aviation Administration rules for aviation workers in 1990 and Federal Railroad Administration requirements in 1991. These regulations established marijuana testing cutoff levels at 50 nanograms per milliliter for initial screening and 15 nanograms per milliliter for confirmatory testing—thresholds that remain unchanged 38 years later despite significant advances in testing technology and pharmacological understanding.

State Medical Marijuana Programs and Employment Conflicts (1996-2012)

California's passage of Proposition 215 in November 1996 created the first direct conflict between state medical marijuana authorization and federal workplace drug testing. The Compassionate Use Act of 1996 permitted physicians to recommend cannabis for serious medical conditions, but provided no explicit employment protections. The California Supreme Court resolved the tension in Ross v. RagingWire Telecommunications, Inc. (2008), ruling that the state medical marijuana law did not require employers to accommodate cannabis use and did not prevent termination based on positive drug tests. By 2012, when Colorado and Washington became the first states to legalize adult-use cannabis, 18 states had enacted medical marijuana programs, yet only a handful provided any employment protections. Arizona's 2010 medical marijuana law included language prohibiting employment discrimination against cardholders, but courts interpreted this narrowly. The Arizona Court of Appeals ruled in Whitmire v. Wal-Mart Stores, Inc. (2014) that employers could still terminate medical marijuana patients who tested positive, as the law only protected against discrimination based on cardholder status, not actual cannabis use or positive drug tests.

Federal Scheduling Debates and Reform Efforts (2013-2024)

The Obama administration's August 2013 Cole Memorandum marked a significant federal policy shift, directing federal prosecutors to deprioritize cannabis enforcement in states with robust regulatory frameworks. However, the memorandum explicitly stated it did not alter the application of federal law, including workplace drug testing requirements. Deputy Attorney General James Cole wrote that the guidance "does not alter in any way the Department's authority to enforce federal law, including federal laws relating to marijuana, regardless of state law." Congressional reform efforts gained momentum with the 2014 Rohrabacher-Farr Amendment, which prohibited the Department of Justice from using funds to prevent states from implementing medical marijuana laws. The provision, renewed annually through appropriations riders, created a patchwork of federal non-enforcement without changing underlying statutes. Representative Earl Blumenauer introduced the Small Business Tax Equity Act in 2017 to address Internal Revenue Code Section 280E, which prohibits cannabis businesses from deducting ordinary business expenses, but the legislation never advanced beyond committee. The Agriculture Improvement Act of 2018 removed hemp—defined as cannabis containing less than 0.3 percent delta-9 THC on a dry weight basis—from Schedule I, creating the first statutory distinction between cannabis varieties based on THC content. The law, signed by President Trump in December 2018, required the Department of Transportation to study hemp-derived CBD and transportation safety, but did not alter marijuana testing requirements. A DOT study released in March 2020 found insufficient evidence to distinguish hemp-derived CBD from marijuana-derived THC in standard workplace drug tests, recommending continued prohibition of all cannabis products for safety-sensitive workers.

Biden Administration Rescheduling Initiative (2022-2025)

President Biden issued a presidential memorandum on October 6, 2022, directing Health and Human Services Secretary Xavier Becerra and Attorney General Merrick Garland to review cannabis scheduling under the Controlled Substances Act. The memorandum cited "failed policies and practices that have led to the imprisonment of countless people, including for simple possession, while not making us any safer" as justification for the review. HHS initiated a scientific and medical evaluation under 21 U.S.C. § 811(b), the statutory provision governing drug scheduling recommendations. The Food and Drug Administration completed its eight-factor analysis in August 2023, concluding that marijuana had accepted medical use in treatment in the United States—a finding that precluded Schedule I classification under the Controlled Substances Act's statutory criteria. The FDA recommended rescheduling marijuana to Schedule III, the classification for drugs with moderate to low potential for physical and psychological dependence, including ketamine, anabolic steroids, and testosterone. The DEA received the HHS recommendation on August 30, 2023, triggering the formal rulemaking process under the Administrative Procedure Act. The DEA published a Notice of Proposed Rulemaking in the Federal Register on May 21, 2024, proposing to reschedule marijuana from Schedule I to Schedule III. The 90-day comment period generated more than 43,000 public submissions, the highest volume for any DEA rulemaking in agency history. Administrative Law Judge John Mulrooney conducted public hearings in December 2024, hearing testimony from medical researchers, patient advocates, law enforcement officials, and industry representatives. The DEA published its final rule on March 15, 2025, with an effective date of April 15, 2025, moving marijuana to Schedule III for the first time since the Controlled Substances Act's enactment in 1970.

Trump Administration Medical Marijuana Reclassification (April 2026)

President Trump's April 2026 executive action represented a further refinement of federal cannabis policy, creating a subcategory within Schedule III specifically for medical marijuana dispensed through state-regulated programs. The action, announced on April 8, 2026, directed the DEA to establish a new drug code for "medical marijuana products dispensed pursuant to valid state medical marijuana programs in accordance with state law." The reclassification applied only to cannabis products distributed through the 38 state medical marijuana programs, not to adult-use recreational products or cannabis obtained through unregulated channels. The Trump administration framed the action as consistent with federalism principles and state sovereignty. White House Press Secretary Karoline Leavitt stated in an April 8 briefing that the policy "recognizes the rights of states to establish their own medical marijuana programs while maintaining federal oversight of recreational use and illegal distribution." The reclassification maintained marijuana's Schedule III status but created regulatory distinctions based on distribution channel and state compliance—a novel approach in federal drug scheduling that legal scholars compared to the hemp carveout in the 2018 Farm Bill. The DOT's May 18, 2026 notice clarified that the April reclassification did not alter transportation workplace drug testing requirements, as those regulations operate under separate statutory authority from the Controlled Substances Act scheduling system.

Legal and Regulatory Framework

Transportation workplace drug testing operates under a complex web of statutes, regulations, and agency guidance that function independently of Controlled Substances Act scheduling decisions. The Omnibus Transportation Employee Testing Act of 1991, codified at 49 U.S.C. § 20140 and related sections, provides the statutory foundation for DOT drug testing. The law requires the Secretary of Transportation to promulgate regulations establishing programs for testing operators of commercial motor vehicles, aircraft, railroad equipment, and other transportation modes for use of alcohol and controlled substances. Critically, the statute defines prohibited substances independently, listing "marijuana" explicitly rather than referencing Controlled Substances Act schedules. This statutory construction insulates DOT testing requirements from DEA scheduling changes. The implementing regulations at 49 CFR Part 40 establish uniform procedures for DOT drug and alcohol testing across all transportation modes. Part 40 specifies that marijuana remains a prohibited drug regardless of state law, medical authorization, or federal scheduling status. Section 40.151(e) states explicitly: "The fact that you may have a valid prescription or medical authorization for a drug does not excuse a positive test result for that drug." This regulatory language, unchanged since 1994, applies to marijuana, cocaine, opioids, and other controlled substances without distinction. Modal-specific regulations add additional layers of requirements. The Federal Motor Carrier Safety Administration's regulations at 49 CFR Part 382 require pre-employment, random, post-accident, reasonable suspicion, and return-to-duty testing for commercial drivers. Random testing must occur at a minimum annual rate of 50 percent of the average number of driver positions, with actual rates adjusted based on industry-wide positive test rates. The Federal Aviation Administration's regulations at 14 CFR Part 120 impose similar requirements on pilots, flight attendants, air traffic controllers, and aircraft maintenance personnel, with random testing rates of 25 percent for drug testing and 10 percent for alcohol testing. The Medical Review Officer role, established in 49 CFR Part 40 Subpart G, provides the only avenue for legitimate medical explanations of positive drug tests. Medical Review Officers—licensed physicians with specialized training in drug testing interpretation—review all positive test results to determine whether legitimate medical explanations exist. However, 49 CFR § 40.151(e) explicitly prohibits MROs from verifying a test as negative based on marijuana prescriptions or medical authorizations, even in states with legal medical cannabis programs. This creates an absolute bar to medical marijuana use for DOT-regulated employees, unlike prescription opioids or amphetamines where valid prescriptions can explain positive results. The Americans with Disabilities Act of 1990, 42 U.S.C. § 12114(a), explicitly excludes current illegal drug use from disability protections, defining "illegal use of drugs" to mean "the use of drugs, the possession or distribution of which is unlawful under the Controlled Substances Act." While marijuana's rescheduling to Schedule III removes it from the most restrictive category, it remains a controlled substance under federal law, and the ADA's exclusion continues to apply. Courts have uniformly rejected ADA claims by medical marijuana patients terminated for positive drug tests, including in Callaghan v. Darlington Fabrics Corp. (2017) and Barbuto v. Advantage Sales and Marketing, LLC. (2017). State employment discrimination laws provide varying levels of protection, creating a patchwork of rights that do not extend to federally regulated transportation workers. Connecticut's Palliative Use of Marijuana Act prohibits employment discrimination against medical marijuana patients, but includes an exception for positions "that could adversely affect the safety of others." New York's Marijuana Regulation and Taxation Act, effective March 2021, prohibits discrimination based on cannabis use outside the workplace, but explicitly exempts positions subject to federal drug testing requirements. These state-level protections cannot override federal DOT regulations under the Supremacy Clause of the U.S. Constitution, Article VI, Clause 2.

Key Players and Stakeholders

Department of Transportation

The Department of Transportation serves as the primary federal agency enforcing workplace cannabis prohibitions for transportation workers. The DOT's Office of Drug and Alcohol Policy and Compliance, led by Director Patrice Kelly, develops policy guidance and oversees compliance across modal administrations. The May 2026 notice clarifying that medical marijuana reclassification does not affect workplace rules represents the agency's consistent position maintained across four presidential administrations. The DOT has resisted calls to adopt impairment-based testing or THC threshold adjustments, citing the lack of scientifically validated impairment correlation and the safety-critical nature of transportation work.

Federal Motor Carrier Safety Administration

The Federal Motor Carrier Safety Administration regulates approximately 3.5 million commercial truck and bus drivers, making it the largest DOT modal administration by workforce size. FMCSA Administrator Robin Hutcheson has emphasized that the agency's drug testing program focuses on safety, not punishment, and that marijuana's federal status changes do not alter the safety rationale for testing. The FMCSA's Drug and Alcohol Clearinghouse, operational since January 2020, maintains a national database of drivers who have violated drug and alcohol testing requirements, creating a permanent record that follows drivers across employers and state lines.

Federal Aviation Administration

The Federal Aviation Administration regulates approximately 900,000 certificated pilots, mechanics, and air traffic controllers. The FAA maintains the most restrictive cannabis policies of any DOT modal administration, with Aviation Medical Examiners required to report any history of cannabis use when evaluating pilots for medical certificates. FAA Administrator Michael Whitaker has stated that the agency will not modify its cannabis policies unless presented with scientifically validated evidence that cannabis use does not impair aviation safety—a standard that current research has not met.

Owner-Operator Independent Drivers Association

The Owner-Operator Independent Drivers Association, representing more than 150,000 small-business truckers, has advocated for cannabis policy reform focused on impairment detection rather than metabolite presence. OOIDA President Todd Spencer has argued that current testing methods punish drivers for off-duty legal cannabis use in states where marijuana is legal, while failing to detect actual impairment. The association has called for research into oral fluid testing and other technologies that could distinguish recent use from residual metabolites, but has not advocated for eliminating testing entirely.

Airlines for America

Airlines for America, the trade association representing major U.S. passenger and cargo carriers, has supported maintaining current DOT drug testing requirements. The organization has emphasized that aviation safety depends on zero-tolerance policies for psychoactive substances, regardless of legal status or medical authorization. A4A has opposed state-level employment protections for cannabis users in safety-sensitive positions, arguing that federal preemption under the Federal Aviation Act of 1958 prevents states from imposing less restrictive standards on aviation workers.

National Organization for the Reform of Marijuana Laws

The National Organization for the Reform of Marijuana Laws has challenged DOT cannabis testing policies as outdated and discriminatory. NORML Deputy Director Paul Armentano has argued that THC metabolite testing cannot establish impairment or predict safety risk, making it an inappropriate basis for employment decisions. The organization has advocated for performance-based impairment testing and has supported litigation challenging workplace cannabis policies, though federal courts have consistently upheld DOT testing requirements.

American Civil Liberties Union

The American Civil Liberties Union has represented transportation workers terminated for medical marijuana use in several high-profile cases. ACLU staff attorney Ezekiel Edwards has argued that federal cannabis policies create a "cruel choice" for patients between effective medical treatment and employment, particularly impacting workers with chronic pain, PTSD, and other conditions for which cannabis provides therapeutic benefit. The ACLU has challenged the scientific basis for marijuana testing, citing studies showing no correlation between THC metabolite presence and impairment or accident risk.

State-by-State Medical Marijuana Employment Protections

State medical marijuana employment protections vary dramatically but cannot override federal DOT testing requirements for transportation workers.

Arizona

Arizona's medical marijuana law, the Arizona Medical Marijuana Act, prohibits discrimination against cardholders but allows employers to terminate employees for positive drug tests. The Arizona Court of Appeals ruled in Whitmire v. Wal-Mart Stores, Inc. (2014) that the law protects cardholder status, not cannabis use or metabolite presence. Arizona permits medical marijuana for qualifying conditions including cancer, glaucoma, HIV/AIDS, chronic pain, and PTSD. Approximately 285,000 active cardholders participate in the program as of May 2026.

California

California provides no employment protections for medical marijuana patients under the Compassionate Use Act of 1996 or the Medical Marijuana Program Act. The California Supreme Court's decision in Ross v. RagingWire Telecommunications (2008) established that employers may enforce drug-free workplace policies and terminate employees for cannabis use regardless of medical authorization. California's adult-use legalization under Proposition 64 in 2016 similarly provided no workplace protections. Assembly Bill 2188, effective January 2024, prohibits discrimination based on off-duty cannabis use detected through hair or urine testing, but explicitly exempts positions requiring federal background checks or federal drug testing.

Connecticut

Connecticut's Palliative Use of Marijuana Act provides the strongest employment protections of any state, prohibiting employers from refusing to hire or terminating employees based solely on medical marijuana patient status. However, the law includes exceptions for positions that "could adversely affect the safety of others" and positions subject to federal regulation. Connecticut courts have not yet addressed whether DOT-regulated transportation positions fall within these exceptions, but federal preemption doctrine suggests state protections cannot override DOT testing requirements. Connecticut has approximately 58,000 registered medical marijuana patients.

Illinois

Illinois's Compassionate Use of Medical Cannabis Program Act prohibits employment discrimination against medical marijuana cardholders but allows employers to enforce drug-free workplace policies and discipline employees for impairment during work hours. The law explicitly states it does not require employers to permit consumption or impairment at work, and does not limit employer rights to discipline for violations of workplace drug policies. The Cannabis Regulation and Tax Act, which legalized adult-use cannabis in 2020, similarly provides limited employment protections while exempting safety-sensitive positions. Illinois has approximately 178,000 active medical marijuana patients.

Massachusetts

Massachusetts provides limited employment protections under a 2017 Massachusetts Supreme Judicial Court decision, Barbuto v. Advantage Sales and Marketing, LLC., which held that employers must consider reasonable accommodations for off-duty medical marijuana use under the state's disability discrimination law. However, the court emphasized that employers need not accommodate cannabis use that would violate federal law or create safety risks. Massachusetts courts have not extended Barbuto protections to federally regulated transportation positions. Massachusetts has approximately 92,000 registered medical marijuana patients and a mature adult-use market.

Nevada

Nevada prohibits employers from refusing to hire applicants based solely on positive pre-employment marijuana tests, under Assembly Bill 132 effective January 2020. The law includes exceptions for safety-sensitive positions, firefighters, EMTs, and positions requiring federal drug testing. Nevada's medical marijuana law provides no additional employment protections beyond the pre-employment testing prohibition. Nevada has approximately 85,000 active medical marijuana cardholders and a significant transportation workforce serving the Las Vegas tourism industry.

New York

New York's Marijuana Regulation and Taxation Act prohibits employment discrimination based on off-duty cannabis use and positive drug tests for cannabis, with exceptions for safety-sensitive positions and federally regulated workers. The law, effective March 2021, represents one of the most comprehensive state-level employment protection schemes, but explicitly preserves employer rights to prohibit cannabis use for positions subject to federal testing requirements. New York has transitioned most medical marijuana patients to the adult-use market, with approximately 125,000 patients remaining in the medical program for access to higher-potency products.

Oklahoma

Oklahoma's medical marijuana law, State Question 788, provides that employers cannot discriminate against medical marijuana license holders but allows employers to discipline employees for possession or use during work hours or for working under the influence. Oklahoma courts have interpreted the law narrowly, permitting termination based on positive drug tests even for off-duty use. Oklahoma has one of the nation's highest per-capita medical marijuana participation rates, with approximately 375,000 active patient licenses in a state of 4 million residents.

Pennsylvania

Pennsylvania's Medical Marijuana Act prohibits employers from discriminating against employees solely on the basis of patient status, but allows discipline for impairment during work hours. The law does not require employers to commit any act that would violate federal law or cause loss of federal contracts or funding. Pennsylvania courts have held that the law does not prevent termination based on positive drug tests, as the statute protects patient status, not cannabis use or metabolite presence. Pennsylvania has approximately 425,000 active medical marijuana patients, one of the largest state programs.

Market and Business Implications

The persistence of federal workplace cannabis prohibitions creates significant labor market distortions and compliance costs across the transportation sector. The American Trucking Associations estimates the commercial driver shortage at 78,000 positions as of May 2026, with projections suggesting the gap could reach 160,000 by 2030 as older drivers retire. Workplace cannabis policies contribute to recruitment challenges, particularly among younger workers who view cannabis use as socially acceptable. A 2025 survey by the Transportation Research Board found that 23 percent of potential commercial driver applicants cited cannabis testing as a deterrent to entering the profession, with the percentage rising to 34 percent among applicants under age 30. Pre-employment drug testing failure rates have increased significantly as state legalization has expanded. FMCSA data from the Drug and Alcohol Clearinghouse shows that 89,000 commercial drivers tested positive for marijuana in 2025, representing 2.5 percent of all drivers tested and a 140 percent increase from 2020 levels. The Federal Aviation Administration reported 1,847 positive marijuana tests among aviation workers in 2025, a 95 percent increase from 2020. These positive tests result in immediate disqualification and require completion of return-to-duty processes that can take months and cost thousands of dollars. Transportation companies face substantial compliance costs for drug testing programs. The Owner-Operator Independent Drivers Association estimates that carriers spend approximately $290 million annually on DOT-mandated drug and alcohol testing, including specimen collection, laboratory analysis, Medical Review Officer services, and administrative overhead. Random testing requirements create logistical challenges for small carriers and owner-operators, who must maintain testing pools and ensure minimum testing rates while managing operational demands. Insurance implications extend beyond direct testing costs. Commercial auto liability insurers have incorporated drug testing compliance into underwriting criteria, with premium discounts of 5-15 percent available for fleets with comprehensive testing programs and positive test rates below industry averages. Conversely, carriers with elevated positive test rates face premium increases of 15-30 percent, and carriers with multiple accidents involving drivers who tested positive for THC may face policy non-renewal. The commercial insurance market has tightened significantly following several high-profile accidents involving cannabis-positive drivers, even where impairment could not be established. The conflict between state medical marijuana programs and federal workplace rules creates perverse economic incentives. States collect substantial revenue from medical marijuana programs through patient registration fees, dispensary licensing, and product taxation. Pennsylvania generated $3.9 billion in medical marijuana sales in 2025, producing $280 million in tax revenue. However, federal workplace prohibitions prevent large segments of the workforce from participating in these programs, limiting program growth and state revenue while pushing patients toward unregulated markets or opioid alternatives. Multi-State Operators in the cannabis industry face unique challenges navigating the intersection of state medical marijuana programs and federal workplace rules. MSOs operating dispensaries in multiple states must maintain DOT compliance for delivery drivers and warehouse workers while advocating for cannabis normalization. Several large MSOs, including Curaleaf, Trulieve, and Green Thumb Industries, have implemented internal policies prohibiting cannabis use by employees in safety-sensitive positions, despite selling cannabis products to patients. This creates cognitive dissonance and employee relations challenges, with some workers viewing the policies as hypocritical.

What Experts Say

Medical researchers, safety experts, and policy analysts offer divergent perspectives on the scientific basis and policy wisdom of maintaining workplace cannabis prohibitions for transportation workers. Dr. Marilyn Huestis, a leading cannabis pharmacology researcher formerly with the National Institute on Drug Abuse, has emphasized that THC metabolite testing cannot establish impairment or predict safety risk. According to research published in Clinical Chemistry, THC metabolites can remain detectable in urine for weeks after use in regular consumers, long after any psychoactive effects have dissipated. Dr. Huestis has advocated for performance-based impairment testing and oral fluid testing, which detects recent use rather than residual metabolites, as more appropriate for safety-sensitive positions. Dr. Igor Grant, director of the Center for Medicinal Cannabis Research at the University of California San Diego, has noted that research shows cannabis impairment typically resolves within 3-4 hours of use for most individuals, though heavy users may experience longer impairment windows. Dr. Grant's research, published in the Journal of Psychopharmacology, found that experienced cannabis users demonstrate less performance impairment than occasional users at equivalent THC blood levels, suggesting tolerance development. However, Dr. Grant has cautioned that individual variation in cannabis metabolism and impairment makes it difficult to establish universal safety thresholds. Mark Rosekind, former administrator of the National Highway Traffic Safety Administration, has defended current DOT testing policies as appropriate given the safety-critical nature of transportation work. According to testimony before the House Transportation and Infrastructure Committee in 2024, Rosekind emphasized that transportation accidents can result in mass casualties and that zero-tolerance policies for psychoactive substances provide clear bright-line rules that are easier to enforce than impairment-based standards. Rosekind noted that alcohol testing uses a 0.04 percent blood alcohol concentration threshold for commercial drivers, well below the 0.08 percent threshold for non-commercial drivers, reflecting the heightened safety standards for professional operators. Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws, has challenged the scientific basis for marijuana metabolite testing in workplace settings. According to a 2025 NORML report, no peer-reviewed research establishes a correlation between THC metabolite presence in urine and impairment, accident risk, or job performance. Armentano has pointed to studies showing that cannabis users have similar or lower accident rates than non-users in some occupational settings, and has argued that testing policies reflect political and cultural biases rather than evidence-based safety practices. Dr. Godfrey Pearlson, director of the Olin Neuropsychiatry Research Center at Yale University, has conducted extensive research on cannabis and driving performance using driving simulators. According to research published in Drug and Alcohol Dependence, cannabis impairs certain driving-related skills including reaction time and lane tracking, but the magnitude of impairment is substantially less than that caused by alcohol at legally prohibited levels. Dr. Pearlson has noted that cannabis users often demonstrate awareness of impairment and compensate by driving more cautiously, unlike alcohol-impaired drivers who tend to overestimate their abilities. Rebecca Haffajee, a health policy researcher at the RAND Corporation, has analyzed the employment implications of conflicting state and federal cannabis policies. According to research published in the Milbank Quarterly, the lack of employment protections for medical marijuana patients creates access barriers that disproportionately affect workers in blue-collar occupations, exacerbating health disparities. Haffajee has noted that patients facing the choice between medical marijuana and employment often choose less effective treatments including opioids, contributing to ongoing addiction and overdose crises.

What's Next

The trajectory of federal workplace cannabis policy will be shaped by congressional action, agency rulemaking, technological advances in impairment detection, and ongoing litigation. Congressional legislation represents the most direct path to resolving conflicts between state medical marijuana programs and federal workplace rules. The Medical Marijuana and Cannabidiol Research Expansion Act, signed into law in December 2022, streamlined research approval processes but did not address employment issues. Representative Earl Blumenauer and Senator Ron Wyden have indicated plans to introduce comprehensive cannabis reform legislation in the current congressional session that would address workplace protections, though prospects for passage remain uncertain given divided congressional control. The Department of Transportation has committed to conducting a comprehensive review of its drug testing program by December 2026, according to statements by DOT Secretary Pete Buttigieg in congressional testimony. The review will examine whether oral fluid testing could supplement or replace urine testing, whether THC testing cutoff levels should be adjusted, and whether alternative approaches to cannabis testing could better balance safety and fairness. However, DOT officials have emphasized that any changes would require extensive research validation and would not eliminate cannabis testing entirely. Technological advances in impairment detection may provide pathways to reform current testing approaches. Several companies, including Hound Labs and SannTek Labs, have developed breathalyzer devices that detect recent cannabis use by measuring THC in breath rather than metabolites in urine. These devices detect THC within a 2-3 hour window after use, more closely correlating with the impairment window than urine testing. The DOT has expressed interest in evaluating these technologies but has not committed to incorporating them into official testing protocols. Litigation challenging workplace cannabis policies continues in state and federal courts. The U.S. Court of Appeals for the First Circuit is expected to rule in 2026 on a case challenging the termination of a medical marijuana patient working for a federal contractor, which could establish precedent on whether federal contractor drug-free workplace requirements override state medical marijuana protections. Several state supreme courts have cases pending that will clarify the scope of state-level employment protections and their interaction with federal regulations. The 2026 midterm elections may shift the political landscape for cannabis reform. Several congressional candidates have made cannabis policy reform central campaign issues, and changes in committee leadership could affect the prospects for reform legislation. State ballot initiatives in several states will address employment protections for cannabis users, potentially creating additional pressure for federal policy changes. International developments may influence U.S. policy. Canada legalized adult-use cannabis in 2018 while maintaining workplace safety protections, and Canadian transportation regulators have developed impairment-based testing protocols that several U.S. researchers have studied as potential models. The United Nations Commission on Narcotic Drugs reclassified cannabis in 2020, removing it from the most restrictive category of controlled substances, and international regulatory harmonization efforts may create pressure for U.S. policy alignment.

Further Reading

• Department of Transportation Drug and Alcohol Testing Regulations, 49 CFR Part 40: https://www.ecfr.gov/current/title-49/subtitle-A/part-40
• Federal Motor Carrier Safety Administration Drug and Alcohol Clearinghouse: https://clearinghouse.fmcsa.dot.gov/
• DEA Final Rule Rescheduling Marijuana to Schedule III (March 2025): https://www.federalregister.gov/
• Controlled Substances Act, 21 U.S.C. § 801 et seq.: https://www.deadiversion.usdoj.gov/21cfr/21usc/
• Americans with Disabilities Act, 42 U.S.C. § 12114: https://www.ada.gov/
• National Institute on Drug Abuse Cannabis Research: https://nida.nih.gov/research-topics/cannabis-marijuana
• American Trucking Associations Driver Shortage Analysis: https://www.trucking.org/
• National Organization for the Reform of Marijuana Laws Employment Resources: https://norml.org/marijuana/employment/
• Transportation Research Board Cannabis and Transportation Safety Research: https://www.trb.org/
• Marijuana Moment Federal Policy Coverage: https://www.marijuanamoment.net/